Literature DB >> 29672406

Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma.

Giuseppe Malleo1, Laura Maggino1, Cristina R Ferrone2, Giovanni Marchegiani1, Mari Mino-Kenudson3, Paola Capelli4, Borislav Rusev5, Keith D Lillemoe2, Claudio Bassi1, Carlos Fernàndez-Del Castillo2, Roberto Salvia1.   

Abstract

OBJECTIVE: First, to assess the impact of the number of examined lymph nodes (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC). Second, to identify the minimum number of ELNs (MNELNs) ensuring an accurate detection of nodal involvement. Third, to reappraise the role of lymph node (LN) parameters, including N-status and lymph node ratio (LNR).
BACKGROUND: In contrast with pancreatoduodenectomy, information on LN staging and the MNELN required in DP is lacking.
METHODS: Patients undergoing DP for PDAC at 2 academic hospitals from 2000 through 2013 were retrospectively analyzed. The eighth edition of the American Joint Committee on Cancer staging system was used. The MNELN was estimated using the binomial probability law. Survival analyses were performed separately for node-negative and node-positive patients using univariable and multivariable models.
RESULTS: The study population consisted of 240 patients. The median number of ELN was 21, significantly lower in node-negative patients as compared with node-positive patients (18.5 vs 24.0; P = 0.001). The proportion of node-positive patients increased with increasing numbers of ELNs, whereas LNR showed an inverse trend. The estimated MNELN was 20. The number of ELN (≥ or <20) was an independent prognostic factor only in node-negative patients [odds ratio (OR) 3.23 for ELN <20), suggesting a stage migration effect. In node-positive patients, N2-class, but not LNR, was a significant predictor of survival at multivariable analysis (OR 1.68).
CONCLUSION: The number of ELN affects nodal staging in body/tail PDAC. At least 20 LNs are required for correct staging. N-status is superior to LNR in predicting survival of node-positive patients.

Entities:  

Mesh:

Year:  2019        PMID: 29672406     DOI: 10.1097/SLA.0000000000002781

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Ammar A Javed; Ding Ding; Erum Baig; Michael J Wright; Jonathan A Teinor; Daniyal Mansoor; Elizabeth Thompson; Ralph H Hruban; Amol Narang; William R Burns; Richard A Burkhart; Kelly Lafaro; Matthew J Weiss; John L Cameron; Christopher L Wolfgang; Jin He
Journal:  World J Surg       Date:  2022-01-07       Impact factor: 3.352

2.  Comment on: oncologic outcomes after robotic pancreatic resections are not inferior to open surgery.

Authors:  Antonio Mimmo; Tullio Piardi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

3.  A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.

Authors:  Jiachen Ge; Lei Li; Zhaolai Ma; Bin Jiang; Chunhui Yuan; Hangyan Wang; Ying Peng; Dianrong Xiu
Journal:  Gland Surg       Date:  2021-01

4.  Distal pancreatectomy outcomes: Perspectives from a community-based teaching institution.

Authors:  Muhammad Umair Bashir; Apostolos Kandilis; Nancy M Jackson; Janak A Parikh; Michael J Jacobs
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-05-31

5.  Prognostic impact of examined lymph node count in pT1N0M0 esophageal cancer: A population-based study.

Authors:  Ying Liu; Heli Yang; Hao Fu; Meng Li; Zhen Feng; Zhongmin Peng; Zhen Liang; Hui Wang
Journal:  Thorac Cancer       Date:  2019-06-24       Impact factor: 3.500

Review 6.  An update on treatment options for pancreatic adenocarcinoma.

Authors:  Aurélien Lambert; Lilian Schwarz; Ivan Borbath; Aline Henry; Jean-Luc Van Laethem; David Malka; Michel Ducreux; Thierry Conroy
Journal:  Ther Adv Med Oncol       Date:  2019-09-25       Impact factor: 8.168

7.  Impact of examined lymph node count on prognosis in patients with lymph node-negative pancreatic body/tail ductal adenocarcinoma.

Authors:  Yu-Feng Li; Yu-Cheng Xiang; Qiu-Qiang Zhang; Wei-Lin Wang
Journal:  J Gastrointest Oncol       Date:  2020-08

8.  Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy.

Authors:  Chen Liu; He Cheng; Kaizhou Jin; Zhiyao Fan; Yitao Gong; Yunzhen Qian; Shengming Deng; Qiuyi Huang; Quanxing Ni; Xianjun Yu; Guopei Luo
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

9.  A Nomogram for Individual Prediction of Poor Prognosis After Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma.

Authors:  Shuyu Zhai; Zhen Huo; Xiayang Ying; Jiabin Jin; Yue Wang; Xiongxiong Lu; Xiaxing Deng
Journal:  Med Sci Monit       Date:  2020-02-23

10.  Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study.

Authors:  Zhen-Jiang Zheng; Mo-Jin Wang; Chun-Lu Tan; Yong-Hua Chen; Jie Ping; Xu-Bao Liu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.